Atlassian uses cookies to improve your browsing experience, perform analytics and research, and conduct advertising. Accept all cookies to indicate that you agree to our use of cookies on your device. Atlassian cookies and tracking notice, (opens new window)
Welcome to the PHUSE Advance Hub

WORKING GROUPS
Results will update as you type.
  • Working Groups
    • Data Transparency
      • Anonymization of Imaging Data
      • Educate the General Population on Data Privacy and Data Sharing
      • EU CTR Implementation
      • Internal Clinical Study Data Sharing Process
      • Patient Data Return
      • PHUSE Stakeholder Review of UK MHRA Clinical Trials Regulation Guidance
      • The Value of Plain Language Summaries of Trial Results
    • Data Visualisation & Open Source Technology
    • Emerging Trends & Innovation
    • Nonclinical Topics
    • Optimizing the Use of Data Standards
    • pharmaverse
    • Real World Evidence
    • Risk Based Quality Management
    • Safety Analytics
  • Hot Topics
  • Useful Information
  • Deliverables
  • Working Groups Events
  • Working Groups Report – Q3 2025
  • Working Groups Archive
  • Working Groups Events Archive

    You‘re viewing this with anonymous access, so some content might be blocked.
    /
    Patient Data Return

      Patient Data Return

      Oct 01, 2025

      Project Scope

      The working group project team will create, disseminate, analyse a survey to Pharmaceutical companies on their clinical trial information and current processes regarding the results. The survey will form the basis of a white paper on the results.

      Problem Statement

      Participant data return is the act of granting clinical trial participants access to the data that was collected about them during a clinical trial.  With the current clinical trial practice, measurements are taken, tests are run, procedures are done, and the results are seen by the investigator and hosted by the sponsor.  The participant, never sees their results.  Once the trial closes and participants wish to get on new medication, the results of their trial are not available to help make this decision.

      Despite significant cross-industry collaboration on this topic by Trancelerate, MRCT, IMI, and EC the adoption of participant data return practices has been slow.  This project aims to highlight current industry practice and identify gaps and challenges.

      Problem Impact

      Clinical Trial Sponsors are increasingly prioritising patient-centricity incorporation of the patient voice in drug development.  At the same time there is growing participant interest in being an active part of research and recognition of the value of the patient’s contribution to clinical research.  As health data becomes more commonplace, there is an increased expectation on sponsors to provide this information back to participants. 

      The inability for participants to know and share their clinical trial data with their medical teams leads to delays and incomplete recommendations for their continued care.  Participant’s doctors cannot understand participant’s data during the clinical trial to make treatment recommendations.

      Specifically to the implementation of PDR in Biopharma companies, lack of knowledge on the general prevailing opinion related to PDR causes each sponsor to create a solution for themselves.  This causes rework and delays in implementing solutions.

       
      Project LeadsEmail 
      Dan Boisvert, BiogenDaniel.boisvert@biogen.com
      Stephen Bamford, Johnson & Johnsonstephen.bamford@phuse.global
      Lucy Marks, PHUSE Senior Project Coordinatorlucy@phuse.global

      CURRENT STATUS (Updated Quarterly) 

      • Survey results have been collected
      • Results will be reviewed within the project team
      Objectives & DeliverablesTimelines
      White Paper DraftQ3 2025
      , multiple selections available, Use left or right arrow keys to navigate selected items
      unrestored-unknown-attachment
      {"serverDuration": 8, "requestCorrelationId": "2eab362686c34000ab28fef86f0609e2"}